Entrada Therapeutics (TRDA) shareholders approve plan changes and re-elect directors
Rhea-AI Filing Summary
Entrada Therapeutics reported the results of its 2026 annual stockholder meeting, held virtually on June 10, 2026. Stockholders approved amendments to the company’s 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan to change the evergreen formulas so that outstanding pre-funded warrants are counted in determining annual share pool increases.
Two Class II directors, Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D., were re-elected to the board. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026. The meeting achieved a quorum, with 33,190,234 of 38,820,616 common shares entitled to vote represented in person or by proxy.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares outstanding entitled to vote: 38,820,616 shares
Shares represented at meeting: 33,190,234 shares
Votes for 2021 Plan Amendment: 14,686,713 votes
+5 more
8 metrics
Shares outstanding entitled to vote
38,820,616 shares
Common stock outstanding as of April 13, 2026 record date
Shares represented at meeting
33,190,234 shares
Common stock present or by proxy at 2026 annual meeting
Votes for 2021 Plan Amendment
14,686,713 votes
Proposal No. 3 stock option and incentive plan amendment
Votes against 2021 Plan Amendment
9,566,186 votes
Proposal No. 3 opposition tally
Votes for 2021 ESPP Amendment
16,780,217 votes
Proposal No. 4 employee stock purchase plan amendment
Auditor ratification votes for
33,132,550 votes
Ratification of Ernst & Young LLP for 2026
Director vote for Peter S. Kim
22,181,490 votes
Election as Class II director, Proposal No. 1
Director vote for Bernhardt Zeiher
22,315,323 votes
Election as Class II director, Proposal No. 1
Key Terms
evergreen provision, pre-funded warrants, broker non-votes, emerging growth company, +1 more
5 terms
evergreen provision financial
"to amend the evergreen provision to provide that the Company’s outstanding pre-funded warrants shall be added"
An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.
pre-funded warrants financial
"the Company’s outstanding pre-funded warrants shall be added to the total number of shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
broker non-votes financial
"BROKER NON-VOTES | --------------------------------------------------------------- | 14,686,713"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
independent registered public accounting firm financial
"to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Entrada Therapeutics (TRDA) announce in this Form 8-K?
Entrada Therapeutics reported the voting results from its 2026 annual stockholder meeting. Stockholders approved amendments to the 2021 equity and employee stock purchase plans, re-elected two Class II directors, and ratified Ernst & Young LLP as independent auditor for 2026.
Did Entrada Therapeutics (TRDA) stockholders approve the 2021 Plan Amendment?
Yes. The 2021 Stock Option and Incentive Plan Amendment was approved with 14,686,713 votes for, 9,566,186 against, 6,562 abstentions, and 8,930,773 broker non-votes. The amendment updates how the evergreen provision is calculated using pre-funded warrants.
Was the 2021 ESPP Amendment approved by Entrada Therapeutics (TRDA) stockholders?
Yes. The 2021 Employee Stock Purchase Plan Amendment passed with 16,780,217 votes for, 7,475,514 against, 3,730 abstentions, and 8,930,773 broker non-votes. It aligns the employee stock purchase plan’s evergreen calculation with the treatment of outstanding pre-funded warrants.
Who was elected to the Entrada Therapeutics (TRDA) board at the 2026 meeting?
Stockholders elected Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. as Class II directors. Each will serve until the 2029 annual meeting of stockholders and until a successor is duly elected and qualified, or earlier death, resignation, or removal.
Did Entrada Therapeutics (TRDA) stockholders ratify the company’s 2026 auditor?
Yes. The appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 received 33,132,550 votes for, 49,650 against, and 8,034 abstentions, indicating strong stockholder support.